UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes

The New England journal of medicine, 2014-10, Vol.371 (15), p.1392-1406

2014

Volltextzugriff (PDF)

In Vivo Alterations in Drug Metabolism and Transport Pathways in Patients with Chronic Kidney Diseases : INDIVIDUALIZED PHARMACOTHERAPY

Pharmacotherapy, 2014, Vol.34 (2), p.114-122

2014

Volltextzugriff (PDF)

Relative bioavailability of tolvaptan administered via nasogastric tube and tolvaptan tablets swallowed intact

American journal of health-system pharmacy, 2013-07, Vol.70 (14), p.1230-1237

2013

Volltextzugriff (PDF)

Pharmacokinetics and safety of fluconazole in young infants supported with extracorporeal membrane oxygenation

The Pediatric infectious disease journal, 2012-10, Vol.31 (10), p.1042-1047

2012

Volltextzugriff (PDF)

Cyclophosphamide and 4‐hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis

British journal of clinical pharmacology, 2012-09, Vol.74 (3), p.445-455

2012

Volltextzugriff (PDF)

Endogenous bile acid disposition in rat and human sandwich-cultured hepatocytes

Toxicology and applied pharmacology, 2012-05, Vol.261 (1), p.1-9

2012

Volltextzugriff (PDF)

Influence of Drug Transport Proteins on the Pharmacokinetics and Drug Interactions of Hiv Protease Inhibitors

Journal of pharmaceutical sciences, 2011-09, Vol.100 (9), p.3636-3654

2011

Volltextzugriff (PDF)

First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial

The Lancet infectious diseases, 2011-04, Vol.11 (4), p.273-283

2011

Volltextzugriff (PDF)

Decreased hepatic breast cancer resistance protein expression and function in multidrug resistance-associated protein 2-deficient (TR⁻) rats

Drug metabolism and disposition, 2011-03, Vol.39 (3), p.441-447

2011

Volltextzugriff (PDF)

In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats

Drug metabolism and disposition, 2010-10, Vol.38 (10), p.1848-1856

2010

Volltextzugriff (PDF)

Evaluation of ⁹⁹mTechnetium-Mebrofenin and ⁹⁹mTechnetium-Sestamibi as Specific Probes for Hepatic Transport Protein Function in Rat and Human Hepatocytes

Pharmaceutical research, 2010-09, Vol.27 (9), p.1987-1998

2010

Volltextzugriff (PDF)

Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian Cancer

Clinical cancer research, 2010-06, Vol.16 (11), p.2999-3010

2010

Volltextzugriff (PDF)

Plasma Bile Acid Concentrations in Patients with Human Immunodeficiency Virus Infection Receiving Protease Inhibitor Therapy: Possible Implications for Hepatotoxicity

Pharmacotherapy, 2010-01, Vol.30 (1), p.17-24

2010

Volltextzugriff (PDF)

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

The New England journal of medicine, 2009-09, Vol.361 (12), p.1139-1151

2009

Volltextzugriff (PDF)

Sex-dependent disposition of acetaminophen sulfate and glucuronide in the in situ perfused mouse liver

Drug metabolism and disposition, 2009-09, Vol.37 (9), p.1916-1921

2009

Volltextzugriff (PDF)

Integration of Preclinical and Clinical Data with Pharmacokinetic Modeling and Simulation to Evaluate Fexofenadine as a Probe for Hepatobiliary Transport Function

Pharmaceutical research, 2009-08, Vol.26 (8), p.1942-1951

2009

Volltextzugriff (PDF)

Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors

Drug metabolism and disposition, 2009-03, Vol.37 (3), p.447-452

2009

Volltextzugriff (PDF)

Relationship between drug/metabolite exposure and impairment of excretory transport function

Drug metabolism and disposition, 2009-02, Vol.37 (2), p.386-390

2009

Volltextzugriff (PDF)

Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2)

Drug metabolism and disposition, 2008-11, Vol.36 (11), p.2219-2226

2008

Volltextzugriff (PDF)

Apparent differences in mechanisms of harmol sulfate biliary excretion in mice and rats

Drug metabolism and disposition, 2008-11, Vol.36 (11), p.2156-2158

2008

Volltextzugriff (PDF)

Effect of albumin on the biliary clearance of compounds in sandwich-cultured rat hepatocytes

Drug metabolism and disposition, 2008-10, Vol.36 (10), p.2086-2092

2008

Volltextzugriff (PDF)

Use of Tc-99m Mebrofenin as a Clinical Probe to Assess Altered Hepatobiliary Transport: Integration of In Vitro, Pharmacokinetic Modeling, and Simulation Studies

Pharmaceutical research, 2008-08, Vol.25 (8), p.1851-1860

2008

Volltextzugriff (PDF)

Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers

Drug metabolism and disposition, 2008-05, Vol.36 (5), p.911-915

2008

Volltextzugriff (PDF)

Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity

Toxicology and applied pharmacology, 2008-04, Vol.228 (1), p.17-23

2008

Volltextzugriff (PDF)

Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice

Drug metabolism and disposition, 2008-01, Vol.36 (1), p.61-64

2008

Volltextzugriff (PDF)

1 – 25 von 84

Suche als RSS-Feed

Aktive Filter

ThemaBiological And Medical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(82)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(84)

Sprache

Englisch
(84)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes

In Vivo Alterations in Drug Metabolism and Transport Pathways in Patients with Chronic Kidney Diseases : INDIVIDUALIZED PHARMACOTHERAPY

Relative bioavailability of tolvaptan administered via nasogastric tube and tolvaptan tablets swallowed intact

Pharmacokinetics and safety of fluconazole in young infants supported with extracorporeal membrane oxygenation

Cyclophosphamide and 4‐hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis

Endogenous bile acid disposition in rat and human sandwich-cultured hepatocytes

Influence of Drug Transport Proteins on the Pharmacokinetics and Drug Interactions of Hiv Protease Inhibitors

First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial

Decreased hepatic breast cancer resistance protein expression and function in multidrug resistance-associated protein 2-deficient (TR⁻) rats

In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats

Evaluation of ⁹⁹mTechnetium-Mebrofenin and ⁹⁹mTechnetium-Sestamibi as Specific Probes for Hepatic Transport Protein Function in Rat and Human Hepatocytes

Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian Cancer

Plasma Bile Acid Concentrations in Patients with Human Immunodeficiency Virus Infection Receiving Protease Inhibitor Therapy: Possible Implications for Hepatotoxicity

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

Sex-dependent disposition of acetaminophen sulfate and glucuronide in the in situ perfused mouse liver

Integration of Preclinical and Clinical Data with Pharmacokinetic Modeling and Simulation to Evaluate Fexofenadine as a Probe for Hepatobiliary Transport Function

Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors

Relationship between drug/metabolite exposure and impairment of excretory transport function

Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2)

Apparent differences in mechanisms of harmol sulfate biliary excretion in mice and rats

Effect of albumin on the biliary clearance of compounds in sandwich-cultured rat hepatocytes

Use of Tc-99m Mebrofenin as a Clinical Probe to Assess Altered Hepatobiliary Transport: Integration of In Vitro, Pharmacokinetic Modeling, and Simulation Studies

Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers

Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity

Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice

Aktive Filter

Suchergebnisse filtern